Doxorubicin is an anthracycline classified among the most effective chemotherapeutics against cancer. It is comprised by 3-amino-2,3,6-deoxy-L-fucose (daunosamine) linked to a quinone-hydroquinone system, and acts by DNA-intercalation, oxidative stress generation and topoisomerase II poisoning. Regardless of its therapeutic value, multidrug resistance and severe cardiotoxicity are important limitations consequential of doxorubicin treatment. To overcome these downsides, new generation analogues have been synthesized, with the carbohydrate moiety being the target of the most successful structural variations in terms of efficacy and toxicity. Based on chemical glyco-diversification, this project will exploit 2-deoxy and 3-amino-2,3-dideoxy glycosides, which are prevalent in many other bioactive natural products, to be combined with doxorubicin aglycone. Four novel glycosides are proposed, which will be prepared by a semi-synthesis approach. Protected doxorubicinone will be the acceptor for alpha-selective catalyzed glycosylations with conveniently manipulated glucals and galactals as glycosyl donors. The analogues prepared will be tested for anticancer activity in a panel of cancer cell lines (HeLa cervical cancer, breast cancer MCF-7 and MDA-MB31 and colon cancer E12 cells) and a model of healthy cells (human lung fibroblasts WI-38).
News published in Agência FAPESP Newsletter about the scholarship: